---
title: "InflaRx (IFRX) to Release Quarterly Earnings on Thursday"
description: "InflaRx (NASDAQ:IFRX) will release its quarterly earnings on Thursday, August 8. Analysts expect earnings of ($0.21) per share for the quarter. InflaRx is a clinical-stage biopharmaceutical company th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/210599815.md"
published_at: "2024-08-02T14:17:32.000Z"
---

# InflaRx (IFRX) to Release Quarterly Earnings on Thursday

> InflaRx (NASDAQ:IFRX) will release its quarterly earnings on Thursday, August 8. Analysts expect earnings of ($0.21) per share for the quarter. InflaRx is a clinical-stage biopharmaceutical company that develops inhibitors for inflammatory diseases. Its lead product candidate is vilobelimab, a novel anti-C5a monoclonal antibody. The company last reported earnings of ($0.19) per share in May, beating analysts' estimates. InflaRx has a market capitalization of $85.96 million.

InflaRx (NASDAQ:IFRX - Get Free Report) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $1.76 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

## InflaRx Price Performance

Shares of NASDAQ:IFRX traded down $0.06 during trading on Friday, reaching $1.46. 7,559 shares of the company were exchanged, compared to its average volume of 191,815. The firm has a market capitalization of $85.96 million, a PE ratio of -1.95 and a beta of 1.58. The business's fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.54. InflaRx has a 12-month low of $1.14 and a 12-month high of $4.30.

## Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of InflaRx in a research report on Monday, June 24th.

**Check Out Our Latest Stock Report on IFRX**

## About InflaRx

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

## Featured Stories

-   Five stocks we like better than InflaRx
-   How to Invest in Small Cap Stocks
-   Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
-   Investing in the High PE Growth Stocks
-   Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
-   Top Biotech Stocks: Exploring Innovation Opportunities
-   Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad)## Should you invest $1,000 in InflaRx right now?

Before you consider InflaRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.

While InflaRx currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [IFRX.US - InflaRx NV](https://longbridge.com/en/quote/IFRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder | InflaRx N.V. is reviving its Phase 3 drug vilobelimab for pyoderma gangrenosum after new analyses indicated potential ef | [Link](https://longbridge.com/en/news/271510982.md) |
| InflaRx Reports Positive Phase 2a Results for INF904 in HS and CSU | InflaRx N.V. reported positive topline data from a Phase 2a study of its anti-inflammatory drug INF904 for hidradenitis  | [Link](https://longbridge.com/en/news/265152684.md) |
| Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results | LifeSci Capital analyst Sam Slutsky has maintained a Hold rating on InflaRx’s IFRX stock due to uncertainties in trial r | [Link](https://longbridge.com/en/news/265549463.md) |
| InflaRx Says Phase 2a Data Support Further Development of INF904 in 2 Skin Conditions | InflaRx (IFRX) announced positive results from a Phase 2a study of INF904 for hidradenitis suppurativa (HS) and chronic  | [Link](https://longbridge.com/en/news/265188065.md) |
| InflaRx (IFRX) Receives a Buy from Leerink Partners | According to TipRanks, Schwartz is a 5-star analyst with an average return of 31.6% and a 53.61% success rate. Schwartz  | [Link](https://longbridge.com/en/news/260148781.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
